Findings

What do systematic reviews say?

39 questions · 39 findings · 21 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 4 · 10.3%GRADE not reported 1 · 2.6%Very low 11 · 28.2%Low 15 · 38.5%Moderate 5 · 12.8%High 3 · 7.7%

IV ferric carboxymaltose vs oral iron

Serious adverse events ‐ mild to moderate disease (16 weeks) · IBD patients

It is very uncertain whether IV ferric carboxymaltose changes serious adverse events ‐ mild to moderate disease (16 weeks) compared with oral iron sulphate (very low certainty).

1 finding from 1 review

Interventions for treating iron deficiency anaemia in inflammatory bowel disease 2021 · Cochrane Headline outcomes only
RR 8.81 [0.52, 149.07]
1 study · 200 participants
Very low

IV iron sucrose vs oral iron

Serious adverse events ‐ mild to moderate disease (16 weeks) · IBD patients

It is very uncertain whether IV iron sucrose changes serious adverse events ‐ mild to moderate disease (20 weeks) compared with oral iron sulphate (very low certainty).

1 finding from 1 review

Interventions for treating iron deficiency anaemia in inflammatory bowel disease 2021 · Cochrane Headline outcomes only
RR 3.07 [0.13, 73.32]
1 study · 91 participants
Very low

IV ferric carboxymaltose vs IV iron

Serious adverse events ‐ mild to moderate disease (12 weeks) · IBD patients

It is very uncertain whether IV ferric carboxymaltose changes serious adverse events ‐ mild to moderate disease (12 weeks) compared with IV iron sucrose (very low certainty).

1 finding from 1 review

Interventions for treating iron deficiency anaemia in inflammatory bowel disease 2021 · Cochrane Headline outcomes only
RR 2.94 [0.12, 71.78]
1 study · 485 participants
Very low

Summary of findings table ‐ Convalescent plasma vs standard plasma

Serious adverse events · individuals with moderate to severe disease

It is very uncertain whether summary of findings table ‐ Convalescent plasma changes serious adverse events compared with standard plasma (very low certainty).

1 finding from 1 review

Convalescent plasma for people with COVID‐19: a living systematic review 2023 · Cochrane Headline outcomes only
RR 0.8 [0.55, 1.15]
3 studies · 327 participants
Very low

Sarilumab vs placebo or usual care

Serious adverse events ( · people with mild/moderate/severe/critical COVID‐19

Sarilumab showed no clear difference in serious adverse events ( compared with standard care/placebo (low certainty).

1 finding from 1 review

Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review 2023 · Cochrane Headline outcomes only
RR 1.09 [0.97, 1.21]
6 studies · 2936 participants
Low

Clazakizumab vs placebo or usual care

Serious adverse events ( · people with mild/moderate/severe/critical COVID‐19

Clazakizumab showed no clear difference in serious adverse events ( compared with standard care/placebo (low certainty).

1 finding from 1 review

Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review 2023 · Cochrane Headline outcomes only
RR 0.69 [0.46, 1.04]
2 studies · 169 participants
Low

Olokizumab vs placebo or usual care

Serious adverse events ( · people with mild/moderate/severe/critical COVID‐19

It is very uncertain whether olokizumab changes serious adverse events ( compared with standard care/placebo (very low certainty).

1 finding from 1 review

Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review 2023 · Cochrane Headline outcomes only
RR 1.25 [0.51, 3.06]
1 study · 248 participants
Very low

Siltuximab vs placebo or usual care

Serious adverse events ( · people with mild/moderate/severe/critical COVID‐19

Siltuximab showed no clear difference in serious adverse events ( compared with standard care/placebo (low certainty).

1 finding from 1 review

Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review 2023 · Cochrane Headline outcomes only
RR 1.29 [0.64, 2.62]
1 study · 148 participants
Low

Levilimab vs placebo or usual care

Serious adverse events ( · people with mild/moderate/severe/critical COVID‐19

Levilimab showed no clear difference in serious adverse events ( compared with standard care/placebo (low certainty).

1 finding from 1 review

Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review 2023 · Cochrane Headline outcomes only
RR 0.5 [0.05, 5.43]
1 study · 206 participants
Low

Tociliuzumab vs placebo or usual care

Serious adverse events ( · people with mild/moderate/severe/critical COVID‐19

It is very uncertain whether tociliuzumab changes serious adverse events ( compared with standard care/placebo (very low certainty).

1 finding from 1 review

Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review 2023 · Cochrane Headline outcomes only
RR 0.93 [0.81, 1.07]
16 studies · 2974 participants
Very low

Tacrolimus vs beclometasone

Serious adverse events · adults with refractory, moderate‐to‐severe ulcerative colitis

Tacrolimus showed no clear difference in serious adverse events compared with beclometasone (low certainty).

1 finding from 1 review

Tacrolimus (FK506) for induction of remission in corticosteroid‐refractory ulcerative colitis 2022 · Cochrane Headline outcomes only
RR 3 [0.13, 71.7]
1 study · 88 participants
Low

Tacrolimus vs placebo

Serious adverse events · adults with refractory, moderate‐to‐severe ulcerative colitis

It is very uncertain whether tacrolimus changes serious adverse events compared with placebo (very low certainty).

1 finding from 1 review

Tacrolimus (FK506) for induction of remission in corticosteroid‐refractory ulcerative colitis 2022 · Cochrane Headline outcomes only
RR 2.44 [0.12, 48.77]
3 studies · 148 participants
Very low

Tacrolimus vs ciclosporin

Serious adverse events · adults with refractory, moderate‐to‐severe ulcerative colitis

The review found no eligible studies for this question.

1 finding from 1 review

Tacrolimus (FK506) for induction of remission in corticosteroid‐refractory ulcerative colitis 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Vitamin D vs placebo or usual care

Serious adverse events · individuals with moderate to severe disease

The review found no eligible studies for this question.

1 finding from 1 review

Vitamin D supplementation for the treatment of COVID‐19: a living systematic review 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Colchicine plus standard care vs placebo or usual care

Serious adverse events ( · individuals with moderate or severe COVID‐19

1 finding from 1 review

Colchicine for the treatment of COVID‐19 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 105 participants
Very low

Oral 5‐ASA vs SASP

Serious adverse events · Patients with active mild to moderate ulcerative colitis

Oral 5‐ASA showed no clear difference in serious adverse events compared with SASP (low certainty).

1 finding from 1 review

Oral 5‐aminosalicylic acid for induction of remission in ulcerative colitis 2020 · Cochrane Headline outcomes only
RR 1.36 [0.28, 6.52]
2 studies · 107 participants
Low

Once daily dosing vs conventional dosing

Serious adverse events · Patients with active mild to moderate ulcerative colitis

Once daily dosing showed no clear difference in serious adverse events compared with conventional dosing (low certainty).

1 finding from 1 review

Oral 5‐aminosalicylic acid for induction of remission in ulcerative colitis 2020 · Cochrane Headline outcomes only
RR 1.34 [0.68, 2.66]
4 studies · 1586 participants
Low

Oral 5‐ASA vs 5‐aminosalicylic acid (5‐ASA) (mesalazine)

Serious adverse events · Patients with active mild to moderate ulcerative colitis

Oral 5‐ASA showed no clear difference in serious adverse events compared with comparator 5‐ASA (low certainty).

1 finding from 1 review

Oral 5‐aminosalicylic acid for induction of remission in ulcerative colitis 2020 · Cochrane Headline outcomes only
RR 0.59 [0.22, 1.56]
4 studies · 677 participants
Low

Oral 5‐ASA vs placebo

Serious adverse events · Patients with active mild to moderate ulcerative colitis

Oral 5‐ASA showed no clear difference in serious adverse events compared with placebo (low certainty).

1 finding from 1 review

Oral 5‐aminosalicylic acid for induction of remission in ulcerative colitis 2020 · Cochrane Headline outcomes only
RR 0.53 [0.18, 1.56]
4 studies · 746 participants
Low

Briakinumab vs placebo

Serious adverse events · people with moderate to severe Crohn's disease in remission

Briakinumab showed no clear difference in serious adverse events compared with placebo (low certainty).

1 finding from 1 review

Anti‐IL‐12/23p40 antibodies for maintenance of remission in Crohn's disease 2019 · Cochrane Headline outcomes only
RR 0.31 [0.03, 3.21]
1 study · 104 participants
Low